Glatiramer acetate-induced lobular panniculitis and skin necrosis.

Abstract

Glatiramer acetate (GA) is a drug that commonly is used for the treatment of relapsing-remitting multiple sclerosis (RRMS). Although it typically is known as a safe and effective therapy, a number of adverse effects associated with GA have been reported in the literature. Local injection-site reactions (LISRs) and mild systemic symptoms are among the most commonly described adverse effects. A review of the literature revealed limited reports of panniculitis as an adverse effect of GA injection and even fewer describing associated skin necrosis. We report a case of GA-induced panniculitis and skin necrosis and discuss the occurrence of panniculitis, necrosis, and lipoatrophy following GA injections.

• Authors: Casey E Watkins, John Litchfield, George Youngberg, Stuart S Leicht, Guha Krishnaswamy
• Journal: Cutis (Cutis) Vol. 95 Issue 3 Pg. E26-30 (Mar 2015) ISSN: 0011-4162 [Print] United States
• PMID: 25844792 (Publication Type: Case Reports, Journal Article)

Chemical References

• Glatiramer Acetate

Topics

• Adult
• Female
• Glatiramer Acetate (adverse effects, therapeutic use)
• Humans
• Multiple Sclerosis, Relapsing-Remitting (drug therapy)
• Necrosis (chemically induced)
• Panniculitis (chemically induced, diagnosis)
• Skin (pathology)